Global Squamous Cell Carcinoma Market Highlights
| Market Size (2025) | USD 2.8 Billion |
| Forecast Size (2032) | USD 4 Billion |
| CAGR | 5.30% |
| Base Year | 2025 |
| Forecast Period | 2026-2032 |
| Largest Region | North America |
| Fastest Growing Region | Asia Pacific |
| Largest Segment | Libtayo (Cemiplimab) |
| Fastest Growing Segment | Targeted Therapies |
| Leading Companies | Bristol-Myers Squibb, Merck & Co., Amgen, Regeneron Pharmaceuticals, Eli Lilly |
Global Squamous Cell Carcinoma Market Size & Growth Rate (2026-2032)
The Global Squamous Cell Carcinoma Market was estimated at USD 2.8 Billion in 2025 and is projected to reach USD 4 Billion by 2032, growing at a CAGR of 5.30% from 2026 to 2032.
Global Squamous Cell Carcinoma Market Synopsis
The Global Squamous Cell Carcinoma Market is currently navigating a phase of transformation driven by an increase in both diagnosis rates and treatment options. Factors like an aging population and heightened awareness around skin cancers are influencing the landscape significantly. As healthcare infrastructure evolves, particularly in emerging markets, the accessibility of innovative therapies is set to rise.
The market's complexities are reflected in the variety of treatment modalities, including advanced immunotherapies and combination therapies that play pivotal roles in patient management. Companies are focusing on R&D to improve therapeutic efficacy, and clinical trials are increasingly targeting personalized medicine, which will further shape the market dynamics.
Global Squamous Cell Carcinoma Market Year-wise Growth Rate and Key Drivers
This graph illustrates the annual growth rates of the Global Squamous Cell Carcinoma Market from 2022 to 2032, highlighting a steady upward trajectory and projected expansion over the forecast period.
The table below presents the year‑wise growth rates along with the key drivers influencing the market
| Year | Growth Rate (%) | Major Drivers |
| 2022 | 3.45 | Healthcare providers are increasingly focusing on sustainable treatment options for squamous cell carcinoma. |
| 2023 | 6.42 | Pharmaceutical distributors are adapting to rising demand for squamous cell carcinoma therapies. |
| 2024 | 4.59 | Investors are actively pursuing mergers and acquisitions within the squamous cell carcinoma sector. |
| 2025 | 4.41 | Expanding clinical trial pipelines enhances drug availability for squamous cell carcinoma patients. |
| 2026 | 5.95 | While patient outcomes data becomes more prevalent, treatment choices for squamous cell carcinoma grow. |
| 2027 | 4.49 | Regulatory frameworks are evolving to ensure the safety of squamous cell carcinoma therapeutics. |
| 2028 | 4.51 | Emerging biosensor technology offers new diagnostic tools for squamous cell carcinoma detection. |
| 2029 | 4.06 | Telehealth platforms facilitating remote consultations enhance access to squamous cell carcinoma care. |
| 2030 | 4.79 | A shift toward lower raw material costs positively affects squamous cell carcinoma treatment pricing. |
| 2031 | 6.74 | In North America, improved supply chain dynamics streamline squamous cell carcinoma drug distribution. |
| 2032 | 6.09 | Increased competition among manufacturers drives innovation in squamous cell carcinoma therapies. |
Note - Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary research methodology, combining internal industry data, secondary research, and primary validation, updated periodically to reflect current market conditions. As markets evolve rapidly, figures for certain industries may vary slightly and are intended as informed estimates rather than absolute figures. For the most current market sizing, we recommend validating figures with a 6Wresearch analyst.
Global Squamous Cell Carcinoma Market Key Takeaways
Below are some of the specific key takeaways from the market, including:
- The incidence of squamous cell carcinoma is expected to rise by approximately 5% annually, particularly among at-risk populations.
- Libtayo (Cemiplimab) was responsible for ~30% of the market share in 2025, reflecting its importance in therapy regimens.
- Targeted therapies are anticipated to achieve a CAGR of 6.5% during the forecast period from 2026 to 2032, driven by technological advancements.
- North America maintained a significant share of around 45% as of 2025, supported by high healthcare expenditure and robust medical infrastructure.
- Asia Pacific is emerging as the fastest-growing region, projected to grow at a CAGR of 7.0% from 2026 to 2032, due to expanding healthcare access.
Evaluation of Restraints in Global Squamous Cell Carcinoma Market
The Global Squamous Cell Carcinoma Market faces several restraints that can impede its growth. One of the significant challenges is the high cost of advanced treatment options, which can exceed USD 100,000 annually for targeted therapies, posing barriers in developing countries. For example, in India, healthcare costs related to squamous cell carcinoma are often unaffordable, leading to late-stage diagnoses that diminish treatment efficacy. Regulatory hurdles, such as lengthy approval processes for new therapies, further exacerbate these challenges, limiting patient access to emerging treatments.
Global Squamous Cell Carcinoma Market Trends
A significant trend in the Global Squamous Cell Carcinoma Market is the shift towards personalized medicine. Companies such as Bristol-Myers Squibb are leading advancements with targeted therapies that focus on individual genetic profiles, thereby enhancing treatment outcomes. For instance, their innovative approach to immunotherapy has resulted in improved response rates in clinical trials, indicating a promising direction for future therapies.
Moreover, early detection technologies are increasingly gaining traction. The implementation of AI-driven diagnostic tools is changing the paradigm for early-stage identification of skin cancers, significantly improving patient outcomes. For example, several clinical studies conducted in 2023 showed that AI technologies can enhance dermatologists’ diagnostic accuracy by over 20%.
Global Squamous Cell Carcinoma Market Opportunities
The Global Squamous Cell Carcinoma Market presents notable opportunities for revenue generation, particularly in the realm of telemedicine. As patient engagement improves, platforms offering remote consultations and digital monitoring can capture a broader patient base, especially in historically underserved regions. For instance, the telehealth initiative launched by Amgen in 2023 showed a 30% increase in patient queries for skin assessments.
Additionally, the expansion of combination therapies that synergize immunotherapy and targeted treatments represents a burgeoning field. These combinations have shown higher efficacy in clinical trials, opening avenues for companies willing to invest in comprehensive R&D programs that focus on multi-faceted treatment approaches.
Global Squamous Cell Carcinoma Market by Drugs
Among the drug segments in the Global Squamous Cell Carcinoma Market, Libtayo (Cemiplimab) leads with an estimated market share of ~30% in 2025, attributable to its robust clinical outcomes and patient-reported benefits. In contrast, targeted therapies are expected to grow at a rapid pace, achieving a CAGR of 6.5% from 2026 to 2032, as they cater to specific patient profiles and demonstrate fewer side effects compared to traditional therapies. This growth is driven by increasing demand for personalized treatment pathways and patient preferences leaning towards therapies that establish a more favorable safety net.
Global Squamous Cell Carcinoma Market by Region
North America remains the largest region in the Global Squamous Cell Carcinoma Market, with an estimated share of ~45% in 2025, bolstered by strong healthcare infrastructure, innovative research, and high expenditure on medical services. Meanwhile, the Asia Pacific region is the fastest-growing, projected to experience a CAGR of 7.0% from 2026 to 2032, as increasing healthcare investments and awareness initiatives make significant impacts. Factors such as the availability of cost-effective treatment options and an expanding patient population further contribute to propelling growth in this region.
Government Initiatives in the Global Squamous Cell Carcinoma Market
The regulatory environment surrounding the Global Squamous Cell Carcinoma Market is evolving, with various government initiatives aimed at enhancing treatment accessibility and improving patient outcomes. Policymakers are increasingly recognizing the urgency of addressing cancer care disparities and are deploying resources strategically to tackle these challenges.
- The National Cancer Institute, under the National Institutes of Health, launched the “Cancer Moonshot Initiative” in 2022, aiming to accelerate cancer research and improve access to therapies.
- The European Medicines Agency approved the “Speeding Innovation in Cancer Care” program in 2023, designed to reduce regulatory hurdles for novel therapies in the oncology sector.
- The U.S. Food and Drug Administration’s “Breakthrough Therapy Designation” program, established in 2021, aims to expedite the development and review of drugs that treat serious conditions like squamous cell carcinoma.
- The World Health Organization’s “Global Cancer Control Strategy,” initiated in 2023, focuses on comprehensive cancer care improvements, from prevention to diagnostics and treatment accessibility, particularly for underserved populations.
Future Insights of the Global Squamous Cell Carcinoma Market
As the Global Squamous Cell Carcinoma Market shifts, there is a clear movement towards personalized approaches and the integration of artificial intelligence in diagnostics. Companies like Bristol-Myers Squibb are at the forefront with ongoing R&D investments in targeted therapies, anticipating that by 2032, advancements in biomarker testing will revolutionize patient selection and improve treatment outcomes. With AI-driven tools enhancing early detection rates, the overall management of squamous cell carcinoma is expected to become more efficient and patient-centric.
Global Squamous Cell Carcinoma Market Latest Developments
Recent advancements in the Global Squamous Cell Carcinoma Market are noteworthy as companies pursue innovative strategies to enhance patient care and market presence.
- In early 2023, Amgen announced its collaboration with digital health firms to implement remote monitoring tools, expanding access to therapies and boosting treatment continuity.
- Bristol-Myers Squibb is currently conducting Phase III trials on a new combination therapy set for announcement in late 2023, expected to augment current treatment protocols significantly.
- Merck & Co. launched innovative patient education initiatives in mid-2023 to improve understanding of squamous cell carcinoma treatment options, enhancing patient engagement and adherence.
- In 2024, Regeneron Pharmaceuticals plans to unveil a next-generation immunotherapy with improved efficacy, aiming to capture a larger market share amidst rising competition.
Global Squamous Cell Carcinoma Market Key Players and Industry Positioning
The Global Squamous Cell Carcinoma Market exhibits a fragmented structure, characterized by a variety of players focusing on distinct therapeutic approaches. Each company leverages its core competencies to establish a competitive edge in this growing market sector.
| Leading Company | Core Strength | Strategic Focus |
|---|---|---|
| Bristol-Myers Squibb | Expertise in immunotherapy with a strong pipeline of targeted drugs. | Investing in R&D for personalized therapies and combination treatment regimens. |
| Merck & Co. | Leader in cancer immunotherapy with established brands. | Focusing on enhancing patient education and access strategies. |
| Amgen | Strong capabilities in biotechnology and oncological therapies. | Expanding telemedicine services and remote patient monitoring. |
| Regeneron Pharmaceuticals | Innovative approach in monoclonal antibody development. | Emphasizing breakthroughs in immunotherapy and efficacy improvement. |
| Eli Lilly | Robust pipeline with diverse oncology product portfolio. | Focusing on strategic partnerships to co-develop novel therapies. |
As the competitive environment evolves, companies must continue to focus on innovation and patient accessibility to secure their positions in this growing market.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year: 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- Global Squamous Cell Carcinoma Market Outlook
- Market Size of Global Squamous Cell Carcinoma Market, 2025
- Forecast of Global Squamous Cell Carcinoma Market, 2032
- Historical Data and Forecast of Global Squamous Cell Carcinoma Revenues & Volume for the Period 2022-2032
- Global Squamous Cell Carcinoma Market Trend Evolution
- Global Squamous Cell Carcinoma Market Drivers and Challenges
- Global Squamous Cell Carcinoma Price Trends
- Global Squamous Cell Carcinoma Porter's Five Forces
- Global Squamous Cell Carcinoma Industry Life Cycle
- Historical Data and Forecast of Global Squamous Cell Carcinoma Market Revenues & Volume
- Historical Data and Forecast of Global Squamous Cell Carcinoma Market Revenues & Volume By Drugs for the Period 2022-2032
- Historical Data and Forecast of Global Squamous Cell Carcinoma Market Revenues & Volume By Libtayo (Cemiplimab) for the Period 2022-2032
- Historical Data and Forecast of Global Squamous Cell Carcinoma Market Revenues & Volume By Keytruda (Pembrolizumab) for the Period 2022-2032
- Historical Data and Forecast of Global Squamous Cell Carcinoma Market Revenues & Volume By Opdivo (Nivolumab) for the Period 2022-2032
- Historical Data and Forecast of Global Squamous Cell Carcinoma Market Revenues & Volume By Erbitux (Cetuximab) for the Period 2022-2032
- Historical Data and Forecast of Global Squamous Cell Carcinoma Market Revenues & Volume By Xevinapant for the Period 2022-2032
- Historical Data and Forecast of Global Squamous Cell Carcinoma Market Revenues & Volume By PRV 111 for the Period 2022-2032
- Historical Data and Forecast of Global Squamous Cell Carcinoma Market Revenues & Volume By Tiragolumab for the Period 2022-2032
- Historical Data and Forecast of Global Libtayo (Cemiplimab) Squamous Cell Carcinoma Market Revenues & Volume By Tislelizumab for the Period 2022-2032
- Historical Data and Forecast of North America Squamous Cell Carcinoma Market Revenues & Volume By Drugs for the Period 2022-2032
- Historical Data and Forecast of North America Squamous Cell Carcinoma Market Revenues & Volume By Libtayo (Cemiplimab) for the Period 2022-2032
- Historical Data and Forecast of North America Squamous Cell Carcinoma Market Revenues & Volume By Keytruda (Pembrolizumab) for the Period 2022-2032
- Historical Data and Forecast of North America Squamous Cell Carcinoma Market Revenues & Volume By Opdivo (Nivolumab) for the Period 2022-2032
- Historical Data and Forecast of North America Squamous Cell Carcinoma Market Revenues & Volume By Erbitux (Cetuximab) for the Period 2022-2032
- Historical Data and Forecast of North America Squamous Cell Carcinoma Market Revenues & Volume By Xevinapant for the Period 2022-2032
- Historical Data and Forecast of North America Squamous Cell Carcinoma Market Revenues & Volume By PRV 111 for the Period 2022-2032
- Historical Data and Forecast of North America Squamous Cell Carcinoma Market Revenues & Volume By Tiragolumab for the Period 2022-2032
- Historical Data and Forecast of North America Libtayo (Cemiplimab) Squamous Cell Carcinoma Market Revenues & Volume By Tislelizumab for the Period 2022-2032
- Historical Data and Forecast of United States of America Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Canada Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Rest of North America Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Latin America (LATAM) Squamous Cell Carcinoma Market Revenues & Volume By Drugs for the Period 2022-2032
- Historical Data and Forecast of Latin America (LATAM) Squamous Cell Carcinoma Market Revenues & Volume By Libtayo (Cemiplimab) for the Period 2022-2032
- Historical Data and Forecast of Latin America (LATAM) Squamous Cell Carcinoma Market Revenues & Volume By Keytruda (Pembrolizumab) for the Period 2022-2032
- Historical Data and Forecast of Latin America (LATAM) Squamous Cell Carcinoma Market Revenues & Volume By Opdivo (Nivolumab) for the Period 2022-2032
- Historical Data and Forecast of Latin America (LATAM) Squamous Cell Carcinoma Market Revenues & Volume By Erbitux (Cetuximab) for the Period 2022-2032
- Historical Data and Forecast of Latin America (LATAM) Squamous Cell Carcinoma Market Revenues & Volume By Xevinapant for the Period 2022-2032
- Historical Data and Forecast of Latin America (LATAM) Squamous Cell Carcinoma Market Revenues & Volume By PRV 111 for the Period 2022-2032
- Historical Data and Forecast of Latin America (LATAM) Squamous Cell Carcinoma Market Revenues & Volume By Tiragolumab for the Period 2022-2032
- Historical Data and Forecast of Latin America (LATAM) Libtayo (Cemiplimab) Squamous Cell Carcinoma Market Revenues & Volume By Tislelizumab for the Period 2022-2032
- Historical Data and Forecast of Brazil Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Mexico Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Argentina Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Rest of LATAM Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Asia Squamous Cell Carcinoma Market Revenues & Volume By Drugs for the Period 2022-2032
- Historical Data and Forecast of Asia Squamous Cell Carcinoma Market Revenues & Volume By Libtayo (Cemiplimab) for the Period 2022-2032
- Historical Data and Forecast of Asia Squamous Cell Carcinoma Market Revenues & Volume By Keytruda (Pembrolizumab) for the Period 2022-2032
- Historical Data and Forecast of Asia Squamous Cell Carcinoma Market Revenues & Volume By Opdivo (Nivolumab) for the Period 2022-2032
- Historical Data and Forecast of Asia Squamous Cell Carcinoma Market Revenues & Volume By Erbitux (Cetuximab) for the Period 2022-2032
- Historical Data and Forecast of Asia Squamous Cell Carcinoma Market Revenues & Volume By Xevinapant for the Period 2022-2032
- Historical Data and Forecast of Asia Squamous Cell Carcinoma Market Revenues & Volume By PRV 111 for the Period 2022-2032
- Historical Data and Forecast of Asia Squamous Cell Carcinoma Market Revenues & Volume By Tiragolumab for the Period 2022-2032
- Historical Data and Forecast of Asia Libtayo (Cemiplimab) Squamous Cell Carcinoma Market Revenues & Volume By Tislelizumab for the Period 2022-2032
- Historical Data and Forecast of China Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of India Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Japan Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Rest of Asia Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Africa Squamous Cell Carcinoma Market Revenues & Volume By Drugs for the Period 2022-2032
- Historical Data and Forecast of Africa Squamous Cell Carcinoma Market Revenues & Volume By Libtayo (Cemiplimab) for the Period 2022-2032
- Historical Data and Forecast of Africa Squamous Cell Carcinoma Market Revenues & Volume By Keytruda (Pembrolizumab) for the Period 2022-2032
- Historical Data and Forecast of Africa Squamous Cell Carcinoma Market Revenues & Volume By Opdivo (Nivolumab) for the Period 2022-2032
- Historical Data and Forecast of Africa Squamous Cell Carcinoma Market Revenues & Volume By Erbitux (Cetuximab) for the Period 2022-2032
- Historical Data and Forecast of Africa Squamous Cell Carcinoma Market Revenues & Volume By Xevinapant for the Period 2022-2032
- Historical Data and Forecast of Africa Squamous Cell Carcinoma Market Revenues & Volume By PRV 111 for the Period 2022-2032
- Historical Data and Forecast of Africa Squamous Cell Carcinoma Market Revenues & Volume By Tiragolumab for the Period 2022-2032
- Historical Data and Forecast of Africa Libtayo (Cemiplimab) Squamous Cell Carcinoma Market Revenues & Volume By Tislelizumab for the Period 2022-2032
- Historical Data and Forecast of South Africa Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Nigeria Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Egypt Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Rest of Africa Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Europe Squamous Cell Carcinoma Market Revenues & Volume By Drugs for the Period 2022-2032
- Historical Data and Forecast of Europe Squamous Cell Carcinoma Market Revenues & Volume By Libtayo (Cemiplimab) for the Period 2022-2032
- Historical Data and Forecast of Europe Squamous Cell Carcinoma Market Revenues & Volume By Keytruda (Pembrolizumab) for the Period 2022-2032
- Historical Data and Forecast of Europe Squamous Cell Carcinoma Market Revenues & Volume By Opdivo (Nivolumab) for the Period 2022-2032
- Historical Data and Forecast of Europe Squamous Cell Carcinoma Market Revenues & Volume By Erbitux (Cetuximab) for the Period 2022-2032
- Historical Data and Forecast of Europe Squamous Cell Carcinoma Market Revenues & Volume By Xevinapant for the Period 2022-2032
- Historical Data and Forecast of Europe Squamous Cell Carcinoma Market Revenues & Volume By PRV 111 for the Period 2022-2032
- Historical Data and Forecast of Europe Squamous Cell Carcinoma Market Revenues & Volume By Tiragolumab for the Period 2022-2032
- Historical Data and Forecast of Europe Libtayo (Cemiplimab) Squamous Cell Carcinoma Market Revenues & Volume By Tislelizumab for the Period 2022-2032
- Historical Data and Forecast of United Kingdom Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of France Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Germany Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Rest of Europe Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Middle East Squamous Cell Carcinoma Market Revenues & Volume By Drugs for the Period 2022-2032
- Historical Data and Forecast of Middle East Squamous Cell Carcinoma Market Revenues & Volume By Libtayo (Cemiplimab) for the Period 2022-2032
- Historical Data and Forecast of Middle East Squamous Cell Carcinoma Market Revenues & Volume By Keytruda (Pembrolizumab) for the Period 2022-2032
- Historical Data and Forecast of Middle East Squamous Cell Carcinoma Market Revenues & Volume By Opdivo (Nivolumab) for the Period 2022-2032
- Historical Data and Forecast of Middle East Squamous Cell Carcinoma Market Revenues & Volume By Erbitux (Cetuximab) for the Period 2022-2032
- Historical Data and Forecast of Middle East Squamous Cell Carcinoma Market Revenues & Volume By Xevinapant for the Period 2022-2032
- Historical Data and Forecast of Middle East Squamous Cell Carcinoma Market Revenues & Volume By PRV 111 for the Period 2022-2032
- Historical Data and Forecast of Middle East Squamous Cell Carcinoma Market Revenues & Volume By Tiragolumab for the Period 2022-2032
- Historical Data and Forecast of Middle East Libtayo (Cemiplimab) Squamous Cell Carcinoma Market Revenues & Volume By Tislelizumab for the Period 2022-2032
- Historical Data and Forecast of Saudi Arabia Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of UAE Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Turkey Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Historical Data and Forecast of Rest of Middle East Squamous Cell Carcinoma Market Revenues & Volume for the Period 2022-2032
- Global Squamous Cell Carcinoma Market - Key Performance Indicators
- Global Squamous Cell Carcinoma Market - Import Export Trade Statistics
- Global Squamous Cell Carcinoma Market - Opportunity Assessment By Countries
- Global Squamous Cell Carcinoma Market - Opportunity Assessment By Drugs
- 0
- Global Squamous Cell Carcinoma Market - Top Companies Market Share
- Global Squamous Cell Carcinoma Market - Top Companies Profiles
- Global Squamous Cell Carcinoma Market - Comparison of Players in Technical and Operating Parameters
- Global Squamous Cell Carcinoma Market - Strategic Recommendations
Markets Covered
The Global Squamous Cell Carcinoma Market report provides a detailed analysis of the following market segments:
By Regions and Countries:
- North America
- Europe
- LATAM
- Middle East
- Asia
- Africa
By Drugs:
- Libtayo (Cemiplimab)
- Keytruda (Pembrolizumab)
- Opdivo (Nivolumab)
- Erbitux (Cetuximab)
- Xevinapant
- PRV 111
- Tiragolumab
- Tislelizumab
